ClinicalTrials.gg

Program

TDI01

A development code. Also written as “TDI01 suspension”.

In Sino Biopharmaceutical's pipeline, ROCK2抑制剂. Its studies are mostly in Idiopathic Pulmonary Fibrosis · Bronchiolitis Obliterans Syndrome, led by Sino Biopharmaceutical.

Furthest: phase 3, since Dec 24, 20253 company-led studies, 3 open or runningNext primary completion: Jul 30, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical33 open or runningphase 3since Dec 24, 2025Jul 31, 2023Jul 30, 2029phase 3 · NCT07464912
  • Named in Sino Biopharmaceutical’s own pipeline as TDI01, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 31, 2023First study: phase 2 study in Idiopathic Pulmonary FibrosisFirst studyNCT06102083 · 120 planned
  2. Dec 5, 2023Phase 2 study in Bronchiolitis Obliterans SyndromeNCT06169722 · 60 enrolled · China
  3. Dec 24, 2025Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedNCT07464912 · 508 planned · China

Ahead

  1. Jul 30, 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07464912

TargetBeta

“ROCK2抑制剂”the company's pipeline, read by Claude · source

Other programs on ROCK2

ProgramCompanyFurthest phaseStudies
belumosudilruleSanofiphase 426
netarsudilruleAlconphase 420

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07464912Idiopathic Pulmonary Fibrosis · China3RecruitingJul 30, 2029508
NCT06169722Bronchiolitis Obliterans Syndrome · China2Active, not recruitingFeb 202660
NCT06102083Idiopathic Pulmonary Fibrosis2Not yet recruitingAug 1, 2025120

How it is read

Names in the registry

  • “TDI01 suspension”, 2 entries
  • “TDI01”, 1 entry

Codes read as this program: TDI01.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.